Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $118.10

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received a consensus recommendation of “Moderate Buy” from the twenty-three ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, twenty-one have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $117.1364.

A number of equities analysts have weighed in on KYMR shares. Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a research report on Monday. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Citigroup upped their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Stephens upped their price objective on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Finally, BTIG Research decreased their price objective on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th.

Kymera Therapeutics Trading Up 6.0%

Shares of Kymera Therapeutics stock opened at $82.96 on Friday. The company has a fifty day moving average price of $82.83 and a 200 day moving average price of $80.17. Kymera Therapeutics has a twelve month low of $36.65 and a twelve month high of $103.00. The stock has a market cap of $6.82 billion, a price-to-earnings ratio of -23.24 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. During the same period in the prior year, the company earned ($0.82) EPS. The firm’s revenue was up 55.5% on a year-over-year basis. Analysts forecast that Kymera Therapeutics will post -3.25 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Bruce Booth sold 5,900 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total value of $530,764.00. Following the sale, the director owned 5,641 shares in the company, valued at approximately $507,464.36. This represents a 51.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $81.18, for a total transaction of $2,435,400.00. Following the completion of the sale, the chief executive officer owned 666,195 shares in the company, valued at approximately $54,081,710.10. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 234,357 shares of company stock worth $19,072,496 over the last quarter. Company insiders own 15.98% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently modified their holdings of KYMR. Baker BROS. Advisors LP raised its stake in shares of Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP acquired a new stake in shares of Kymera Therapeutics in the 3rd quarter valued at about $47,563,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.